Proxy advisory firms Institutional Shareholder Services and Glass Lewis on Friday said shareholders of Bristol-Myers Squibb Co should vote in favor of the drugmaker’s proposed $74 billion takeover of rival Celgene Corp., which has been opposed by one of its largest investors and an activist hedge fund.